Products
Pre-made Sotrovimab benchmark antibody ( Whole mAb, anti-SARS-CoV-2 Spike RBD therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-530
Pre-Made Sotrovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sotrovimab is an investigational monoclonal antibody therapy medication with activity against SARS-CoV-2. It is under development by GlaxoSmithKline and Vir Biotechnology, Inc.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-530-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size： 1mg | 10mg | 100mg
Description
| Products Name (INN Index) | Pre-Made Sotrovimab biosimilar, Whole Mab: Anti-SARS-CoV-2 Spike RBD therapeutic antibody |
| INN Name | Sotrovimab |
| Target | SARS-CoV-2 Spike RBD |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | 7jx3:AB/6ws6:EF/6wps:CD:FG:HL/6wpt:DE:HL |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | na |
| Companies | GlaxoSmithKline;Vir Biotechnology |
| Conditions Approved | COVID-19 |
| Conditions Active | na |
| Conditions Discontinued | na |
| Development Tech | na |
<